



Innovative Therapeutics Targeting Serious Viral Diseases

JUNE 2024

Cautionary note regarding forward-looking statements

The information in this presentation contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio's ability to realize the potential benefits of its collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments; Assembly Bio's ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio's collaboration with Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio's product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio's product candidates from other companies' candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio's reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio's risks and uncertainties are more fully detailed under the heading "Risk Factors" in Assembly Bio's filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Assembly Bio is advancing the treatment paradigm in serious viral diseases



TWO INVESTIGATIONAL THERAPIES IN CLINICAL STUDIES TWO ADDITIONAL CANDIDATES EXPECTED TO ENTER THE CLINIC BY END OF 2024

- Focused on areas with high unmet medical need and significant market opportunity
- Interim data from two studies anticipated by end of 2024
- Interim Phase 1b data for ABI-5366 expected in 1H2025



EXPERIENCED LEADERSHIP AND VIROLOGY-FOCUSED R&D ORGANIZATION

R&D team with over 15 approved drugs in viral disease and hepatitis



INDUSTRY LEADING PARTNER IN GILEAD

 Collaboration brings together the teams' expertise in virology and provides assets, funding, and an established partner for late stage development and commercialization


Differentiated pipeline of candidates targeting herpesviruses and viral hepatitis





2024 key objectives and anticipated progress

Expect four development candidates in the clinic by end of 2024






Development Programs



ABI-5366 and ABI-1179



Long-acting HSV helicase-primase inhibitors (HPIs) for recurrent genital herpes

ABI-5366 Phase 1a/1b study initiated
ABI-1179 anticipated to enter the clinic by end of year


7

Recurrent genital herpes is a significant medical need with limited treatment options that ABI-5366 can address

MEDICAL NEED IS SIGNIFICANT AND CURRENT TREATMENT IS ONLY PARTIALLY EFFECTIVE



4M+ in US & EU with initial symptomatic genital herpes infection have 3+ recurrences/year¹⁻⁶




Suppressive SOC is 1-gram daily valacyclovir, viral polymerase inhibitor approved 1995⁷



Only 1 in 3 with frequent outbreaks^a remain recurrence free for a year on SOC⁷

ABI-5366 HAS POTENTIAL TO DELIVER SIGNIFICANT VALUE TO INDIVIDUALS WITH HSV





Targeting a suppressive therapy for recurrent genital herpes with **superior efficacy** to SOC in reducing outbreaks and **once weekly oral dosing**

>\$1 billion market opportunity for recurrent disease

Additional opportunities:



Episodic treatment



Orofacial



Prevention of transmission




Long-acting injectable



In a study of patients with 6 or more annual recurrences; did not include discontinued, withdrawn, or lost in follow-up

As a long-acting therapy for recurrent genital herpes, ABI-5366 has the potential to improve uptake, adherence, and efficacy






- 72% of HSV patients with recurrent outbreaks prefer suppressive therapy to episodic¹
- Long-acting therapy consistent drug levels, better compliance²
 - Medication non-adherence for chronic illness is ~50% with stigma, AE anxiety, high dosing frequency being common barriers³
 - Superior efficacy shown for long-acting therapy in HIV in individuals with a history of adherence challenges⁴



HSV helicase-primase inhibition is a clinically validated mechanism that has shown improved efficacy to SOC in investigational studies

- Helicase-primase is an essential HSV enzyme complex with no host equivalent
- Clinically-validated mechanism
 - Pritelivir showed greater reductions in HSV shedding, fewer days with lesions & pain vs. approved SOC in investigational studies¹
- Active against SOC resistant HSV
- Assembly Bio's candidates active against both
 - HSV-2 (leading cause of genital herpes)
 - HSV-1 (leading cause oral-facial herpes)



Wald, et al. JAMA 2016 QD, once daily; SOC, standard of care

ABI-5366's preclinical potency, PK, and safety profile support long-acting administration; Phase 1a/1b study initiated

Highly potent in antiviral assays


Critical properties for long-acting

- Projected human half-life of >7 days¹
- Potential for long-acting oral & injectable formulations


Favorable preclinical safety profile

Phase 1a/1b study initiated


- Interim Phase 1a data expected in Q3
- Interim Phase 1b data expected in 1H2025



ABI-5366 400-fold more potent than acyclovir against both HSV-1 and HSV-2 isolates



Study ABI-5366-101: Phase 1a/b design



- Phase 1a will evaluate single ascending doses in healthy participants
- PK data enable evaluation against target concentrations for antiviral efficacy and QW dosing profile

- Phase 1b will evaluate once-weekly oral doses in participants seropositive for HSV-2 with recurrent genital herpes
- Efficacy endpoints include viral shedding and clinical outcomes

Interim Phase 1a data expected in Q3 2024 | Interim Phase 1b data expected in 1H2025

ABI-1179 expands long-acting helicase-primase inhibitor portfolio and strengthens potential to change treatment paradigm for recurrent genital herpes



Structurally distinct HSV helicase-primase inhibitor licensed from Gilead




GLP tox ongoing; preclinical potency, PK and safety profile to date support a once weekly tablet



Clinical studies targeted to initiate by end of 2024





ABI-6250: Oral hepatitis D virus entry inhibitor

Expected to enter the clinic by end of 2024

Chronic HDV is a serious life-threatening disease and major unmet need with limited treatment options



12 **–** 72 million

PEOPLE ESTIMATED TO BE CHRONICALLY INFECTED WITH HDV GLOBALLY¹

70% progress to cirrhosis within 10 years²



Very limited treatment options

BULEVIRTIDE, LARGE MOLECULE ENTRY INHIBITOR, ONLY APPROVED DRUG (EU ONLY)

Safe and highly effective in long-term clinical trials, but requires daily injection and cold storage




ABI-6250, an opportunity to simplify treatment

SMALL MOLECULE TARGETING SAME MECHANISM AS BULEVIRTIDE


An oral treatment is expected to further enhance treatment uptake and diagnosis rates


1. Negro & Lok 2023; 2. WHO 2023.

Inhibition of HDV entry lowers viral load and normalizes ALT




ABI-6250: potent pan-genotypic preclinical activity against HDV with projected QD PK





ABI-6250: exceeded target therapeutic plasma concentrations when given orally to preclinical species¹



Initiation of ABI-6250 clinical studies anticipated by end of 2024





ABI-4334: Next-generation CAM for hepatitis B

Phase 1b study initiated

HBV is a major unmet medical need



HBV PREVALENCE:

254M¹



DIAGNOSED:

33M¹



TREATED:

7M¹

Up to 1,100,000 people

DIED IN 20221 FROM HBV-RELATED CAUSES

Treatments are life-long

INHIBIT VIRUS BUT CURE RATES VERY LOW


Opportunity to improve outcomes

AND INCREASE NUMBER OF PATIENTS DIAGNOSED
AND TREATED, with development of finite and curative therapies

No new MOAs approved for HBV in >25 years


1. WHO (2024)


Capsid Assembly Modulators (CAMs) have two mechanisms of action; a key differentiator is potency against the 2nd mechanism



ABI-4334 observed to be >1000x more potent against cccDNA formation *in vitro* than the 1st gen CAM vebicorvir

ABI-4334 demonstrated high *in vitro* potency against both mechanisms of action for CAMs






Compared to 1st-gen CAM vebicorvir (VBR), next-generation CAM ABI-4334 was observed to be:

- > 500x more potent against MOA #1
- > 1000x more potent against MOA #2

4334 Phase 1a data observed supports high potency against both mechanisms of action




Well-tolerated safety profile with linear PK

	4334 Ph1a Cohorts ¹	
Parameters	100mg ^a	200mg ^a
C _{min,} ng/mL	119	263
Fold above paEC ₅₀ MOA #1 (antiviral)	79x	175x
Fold above paEC ₅₀ MOA #2 (cccDNA)	15x	34x

A Based on observed data on day 8

C_{min} of 34x paEC₅₀ for MOA #2 at 200 mg QD

Study ABI-4334-102: Phase 1b design



- Study will enroll HBeAg-positive or HBeAg-negative cHBV infected participants not on NrtI
- Each cohort will enroll 8 active and 2 placebo participants
- Participants will receive once daily dosing with ABI-4334 or placebo for 28 days
- Endpoints include measures of antiviral efficacy (HBV DNA)

4334 Phase 1b interim data expected by end of 2024



Research Pipeline





Oral pan-herpes non-nucleoside polymerase inhibitor (NNPI) for transplant-associated herpesviruses

Multiple herpesviruses can cause significant morbidity and mortality in immunocompromised transplant recipients

60,000 PATIENTS AFFECTED¹

AMONG TRANSPLANT PATIENTS:



Lifelong latent infections

FREQUENTLY REACTIVATE DURING IMMUNOSUPPRESSION

Uncontrolled viral replication

AND SEVERE DISEASE DURING REACTIVATION

Risk of graft loss and death

SOC antivirals are:

- PARTIALLY EFFICACIOUS
- NOT BROAD SPECTRUM
- HAVE TOLERABILITY AND DRUG INTERACTION LIMITATIONS

An oral pan-herpes antiviral could improve efficacy and greatly simplify treatment

Patel and Paya. Clin. Microbiol. Rev. 1997; Breuer, et al. Mol. Diagn. Ther. 2012; Clark, et al. Semin. Respir. Crit. Car Med. 2013; Haidar and Singh. Curr. Opin. Infect. Dis. 2019; Beyar-Katz et al. Clin. Microbiol. Infect. 2020; Kwon et al. Transp. Infect. Dis. 2021; Wutzler et al. Nev. Diagn. Ther. 2010; Lanzieri et al. Int. J. Gynaecol. Obstet. 2016; Lachmann et al. PLoS One 2018; Patton et al. Clin. Infect. Dis. 2018; Ayoub et al. BMC Med. 2019; Zuhair et al. Rev. Med. Virol. 2019; Zhang et al. Virol. 2019; Marty et al. NEJM. 2021; Mitzle et al. Transp. 2012; Witzle et al. Transp. 2018

Assembly Bio's oral pan-herpes polymerase inhibitor program is designed to provide significant innovation over current standard of care


Conserved viral polymerase offers potential for broad-spectrum herpesvirus inhibitors

Opportunity to advance over current standard of care

- Improve efficacy
- Simplify treatment (1 agent to target 4 viruses)
- Improve tolerability and reducing drug-drug interactions


Gilead collaboration expands portfolio and augments program

- Assembly and Gilead contribute extensive expertise and active programs
- Combined effort anticipated to speed candidate nomination and enhance chance for clinical success



Multiple series of potent, broad-spectrum herpesvirus inhibitors identified






Oral, liver-focused IFNAR agonist for hepatitis B and hepatitis D

A small-molecule liver-focused IFNAR agonist could provide significant innovation over current standard of care

IFN- α is an approved therapy for HBV and associated with functional cure in some patients; however, tolerability limits its use

Small molecule agonists identified which closely mimic IFN-α biology, including ISG induction *in vitro* and *in vivo*


Selectively activating the IFN- α pathway in the liver (vs systemically) is expected to significantly improve tolerability





Lead optimization of multiple IFN- α receptor agonists in progress





Gilead Collaboration

Assembly-Gilead partnership combines Gilead's pioneering vision with Assembly's deep R&D expertise to bring next-gen virology medicines to patients



Brings together the two team's knowledge and expertise in antiviral research, clinical development, and commercialization



Strengthened portfolio with two programs targeting HSV and transplant-associated herpesviruses received from Gilead



Extends Assembly's cash runway with total upfront cash payment and equity investment of \$100 million, plus potential future payments receivable from Gilead



- ✓ Leader in antivirals, with a track record in developing transformative medicines, cures and access strategies
- ✓ Innovative medicines have helped to transform the lives of those living with viral hepatitis, having developed a cure for hepatitis C while continuing to develop new treatments for chronic hepatitis B and D



✓ Deep R&D expertise and agile, experienced team that has rapidly discovered and developed a promising portfolio of compounds designed to address unmet needs in herpesviruses and hepatitis B and D

Partnership overview



KEY FINANCIALS

\$100M Total Upfront Consideration

~\$85M cash and ~\$15M equity investment

Potential additional equity purchase at a premium Contingent Payments Per Program

- Opt-in fee of at least \$45M per program
- Regulatory & commercial milestones up to \$330M

Royalties

High single-digits to high-teens

40% US profit/cost share option on all programs

\$75M Collaboration Extension Payments

• 3rd, 5th, and 7th years of the collaboration

STRUCTURE

Long-Term Partnership and Collaboration

- Assembly contributes all current and future programs
- Gilead contributes two herpesvirus programs

Responsibilities and Options

- Assembly primarily responsible for R&D before opt-in
- Gilead may opt-in to each program, with ability to extend option from end of Phase 1 to end of Phase 2
- Gilead controls all development and commercialization after exercise of the option
- Assembly may opt-in to US cost/profit share and co-promote for certain programs
- Assembly may continue development or license programs upon Gilead opt-out





Nasdaq: ASMB